Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787704 | 0.79 | BAZ2B (0.66) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL357627 | 0.78 | BAZ2B (0.63) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL222289 | 0.78 | BAZ2B (0.63) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL25815441 | 0.77 | BAZ2B (0.53) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL12083938 | 0.77 | BAZ2B (0.53) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL2757921 | 0.77 | BAZ2B (0.67) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL1080282 | 0.76 | BAZ2B (0.61) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL1555279 | 0.76 | BAZ2B (0.61) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL193910 | 0.76 | BAZ2B (0.61) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL25552307 | 0.75 | AURKA (0.38) | BAZ2BKDM4EKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144890-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY | MyricX Pharma Limited (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4741393-A2 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | MyricX Pharma Limited (GB) | 2026-04-14 | — | — | US | disclosed |
| US-20260083858-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR AND ITS USE | MYRICX PHARMA LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4707278-A2 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| US-20260049075-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| EP-4583979-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4583919-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR AND ITS USE | MyricX Pharma Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| CN-119997982-A | Antibody drug conjugates comprising NMT inhibitors and uses thereof | 迈里克斯制药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119968369-A | Cytotoxic imidazo [1,2-a ] pyridine compounds and their use in therapy | 迈里克斯制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024052685-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052684-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR AND ITS USE | MyricX Pharma Limited (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052685-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8624040-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | BAZ2B 171/4885KDM4E 903/4885RAB9A 2388/4885 |
| US-20260083858-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR AND ITS USE | NMT1, CSGALNACT1, NMT2 | BAZ2B 3057/4885KDM4E 2098/4885RAB9A 959/4885 |
| US-20260049075-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | XPA, FLT3, TPMT | BAZ2B 4062/4885KDM4E 1532/4885RAB9A 1696/4885 |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | SLC7A1, FLT3, ABL1 | BAZ2B 4524/4885KDM4E 2143/4885RAB9A 1210/4885 |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | ABL1, FLT3, MTX2 | BAZ2B 4541/4885KDM4E 2699/4885RAB9A 1057/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | BAZ2B 171/4885KDM4E 903/4885RAB9A 2388/4885 |
| US-20260144890-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY | TOP1, NMT1, NMT2 | BAZ2B 3253/4885KDM4E 1668/4885RAB9A 1909/4885 |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | BAZ2B 2013/4885KDM4E 2743/4885RAB9A 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.